MMP-18 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human MMP-18 (Collagenase-4, MMP1, UniProt P03956) expressed in HEK293 cells. Suited for collagenase activity assays, inhibitor IC50 determination, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-MMP18

In stock

SKU
REC-MMP18
$498.00

Target Overview

MMP-18 (also catalogued under gene symbol MMP1, UniProt P03956) is a secreted zinc-dependent endopeptidase belonging to the matrix metalloproteinase family. The full-length human sequence spans 469 amino acids and encodes a signal peptide, propeptide, catalytic domain containing the conserved HEXXH zinc-binding motif, and a C-terminal hemopexin-like domain. This recombinant is produced in HEK293 mammalian cells, a host system that supports the glycosylation and disulfide-bond formation characteristic of the native secreted enzyme — features that are relevant when using the protein as a substrate-cleavage standard or as an antibody validation control. MMP-18 cleaves fibrillar collagens of types I, II, and III at a single site within the triple-helical domain, and has additionally documented activity against type VII and type X collagen. As with other classical collagenases, initial cleavage of the triple helix generates three-quarter and one-quarter fragments that denature spontaneously at physiological temperature and become susceptible to gelatinolytic secondary digestion. In the laboratory, this recombinant is primarily used in three contexts: (1) collagenolytic activity assays using fluorescently labelled or DQ-collagen substrates; (2) inhibitor potency measurements, where the defined specific activity of the preparation enables reproducible IC50 determinations; and (3) as a positive-control antigen for antibody validation by Western blot or ELISA. Researchers requiring an antibody to pair with this recombinant for validation experiments can reference the matched Triple Point Biologics antibody reagent (SKU: RP-MMP18), which is validated for Western blot against human MMP-18.

Background

Matrix metalloproteinase-1 (MMP1/MMP-18) is one of the founding members of the MMP family and remains among the most extensively characterised interstitial collagenases in biomedical research. Its principal biochemical role is the rate-limiting cleavage of native fibrillar collagen — types I, II, and III — at a single Gly–Leu/Ile peptide bond approximately three-quarters from the N-terminus of the triple-helical domain. This initial nick is sufficient to destabilise the triple helix at body temperature, rendering the fragments accessible to gelatinases and other downstream proteases. Activity against type VII and type X collagen has also been documented in published literature (PubMed: 1645757, 2153297, 2557822). In tissue remodelling research, MMP-18/MMP1 has been studied as a component of the extracellular matrix (ECM) turnover machinery active during wound healing, organ fibrosis, tumour stroma remodelling, and reproductive tissue remodelling. In the context of preterm birth research, protease signatures including MMP1 have been examined in cervicovaginal environments characterised by dysbiosis and inflammation (Hong et al., Front Immunol, 2026). In oncology-related basic research, stress-induced changes in Mmp1 gene methylation status have been characterised in rat tumour models (Borikun, Exp Oncol, 2026), illustrating how epigenetic regulation of MMP1 expression is studied as a mechanistic variable. MMP-18/MMP1 is also a well-established research target in studies of skin ageing, where it functions as the primary collagen-degrading enzyme in UV-irradiated or chronologically aged dermis. Published inhibitor discovery work has screened peptide libraries against MMP-1 activity using recombinant enzyme preparations as the assay target — for example, a study on anti-skin-ageing peptides from Camelus bactrianus placenta employed MMP-1 inhibition as a primary readout (Tian et al., J Ethnopharmacol, 2026). Additionally, network pharmacology and molecular docking studies investigating traditional medicine formulations in rheumatoid arthritis have identified MMP1 among the key protease nodes characterised in silico and experimentally (Xu et al., Curr Pharm Des, 2026). Beyond connective tissue biology, published work has documented an interaction between MMP1 and HIV-encoded Tat protein in the context of neuroinflammation research, where secreted Tat cleavage by MMP1 was studied as a potential modulator of neurotoxicity (PubMed: 16807369). This breadth of research contexts — spanning dermatology, reproductive biology, oncology, and infectious disease models — reflects the wide deployment of recombinant MMP1 preparations across basic and translational research programmes.

Applications

  • Collagenase activity assay using fluorescently labelled (DQ) collagen type I, II, or III substrate
  • Inhibitor IC50 determination in biochemical small-molecule or peptide screening assays
  • Positive-control antigen for Western blot validation of anti-MMP1/MMP-18 antibodies (pair with SKU RP-MMP18)
  • ELISA standard curve calibration for quantification of MMP-18 in conditioned media or tissue lysates
  • Substrate specificity profiling by mass spectrometry-based degradomics
  • Zymography loading control for MMP activity gel assays
  • Competitive binding and surface plasmon resonance (SPR) studies of MMP-1–inhibitor interactions
  • Recombinant antigen for immunisation or antibody specificity confirmation by dot blot

References

  1. Xu R et al. Combining Network Pharmacology, Machine Learning, Molecular Docking, and Experimental Validation to Explore the Mechanism of Danggui-Shaoyao-San in treating Rheumatoid arthritis. Curr Pharm Des. 2026. doi:10.2174/0113816128431656260305144620. PMID: 42337901.
  2. Hong S et al. Vaginal dysbiosis and inflammatory signatures in preterm labor: an integrated model for predicting preterm birth. Front Immunol. 2026. doi:10.3389/fimmu.2026.1809046. PMID: 42327783.
  3. Wang N et al. Identification of Biomarker in Kidney Stone Disease by Integrating Transcriptomics and Olink Proteomics: A Case-Control Study. J Inflamm Res. 2026. doi:10.2147/JIR.S605025. PMID: 42306184.
  4. Tian L et al. Targeted discovery of anti-skin aging peptides from Camelus bactrianus placenta: Multi-activity screening, network pharmacology, and in vitro validation focusing on MMP-1 inhibition. J Ethnopharmacol. 2026. doi:10.1016/j.jep.2026.122064. PMID: 42302941.
  5. Borikun T. Stress-Induced Changes in the Methylation Status of Mmp1 and Mmp8 Genes in Tumor Tissue of Rats with Guerin Carcinoma. Exp Oncol. 2026. doi:10.15407/exp-oncology.2026.01.046. PMID: 42290557.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What is the expected molecular weight of recombinant MMP-18 on SDS-PAGE or Western blot?

The full-length human MMP-18 sequence encodes 469 amino acids with a predicted unglycosylated molecular weight of approximately 54 kDa. Because this recombinant is produced in HEK293 cells, N-linked glycosylation shifts the apparent MW to roughly 57–60 kDa under denaturing, reduced SDS-PAGE conditions. If you are running the active, propeptide-cleaved form, expect a band near 47–50 kDa. Always include a reducing agent in sample buffer; the hemopexin-like domain contains disulfide bonds that will retard migration under non-reducing conditions and can produce anomalous high-MW smearing.

Does recombinant MMP-18 include the propeptide, and which processing form is supplied?

The recombinant MMP-18 (REC-MMP18) is supplied as the active enzyme with the signal peptide and prodomain removed — equivalent to the mature secreted collagenase form found in conditioned medium after autocatalytic or furin-mediated activation. The catalytic domain and C-terminal hemopexin-like domain are both present. If your experiment requires the zymogen (full pro-form) for activation kinetics studies, this product is not the appropriate format. The active enzyme is suitable for direct collagen-cleavage assays or as a Western blot band-size standard without a separate APMA activation step.

What collagen substrates and cleavage sites does recombinant MMP-18 act on?

MMP-18 is a classical collagenase that cleaves fibrillar type I, II, and III collagens at a single Gly~Ile/Leu scissile bond within the triple-helical domain, generating characteristic three-quarter and one-quarter fragments. Documented activity also extends to type VII and type X collagen. For fluorometric activity assays, use a collagen-mimetic FRET substrate such as Mca-PLGL-Dpa-AR-NH2 (MMP collagenase consensus peptide); activity is detectable at enzyme concentrations as low as 1–5 nM with this substrate under standard assay conditions.

What assay buffer should I use for MMP-18 collagenase activity assays?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol — is compatible with direct use in activity assays. For fluorometric FRET substrate assays, dilute REC-MMP18 into assay buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, and 0.05% Brij-35 to prevent surface adsorption at low enzyme concentrations. Maintain CaCl₂ at ≥1 mM; calcium is required for structural stability of the zinc-containing catalytic domain. Avoid EDTA or EGTA; they chelate zinc and calcium and will abolish activity within minutes.

What starting concentration of recombinant MMP-18 is recommended for a peptide substrate activity assay?

A good starting point is 5–20 nM REC-MMP18 with 5–20 µM FRET peptide substrate (e.g., Mca-PLGL-Dpa-AR-NH2) in a 100 µL reaction at 37°C. Monitor fluorescence at Ex/Em 320/405 nm and confirm linearity over 30–60 minutes before calculating specific activity. For IC50 determination of MMP inhibitors, use 5 nM enzyme to remain well below substrate Km and satisfy the Morrison tight-binding correction threshold. At concentrations above 50 nM, auto-inhibition or substrate depletion can compress the dynamic range of inhibitor dose-response curves.

Can recombinant MMP-18 be used as a positive control for Western blot with the RP-MMP18 antibody?

Yes — REC-MMP18 and the matched rabbit polyclonal antibody RP-MMP18 (/anti-mmp-18-rabbit-polyclonal-antibody) are validated together from the same laboratory, specifically for this purpose. Load 10–50 ng of REC-MMP18 per lane alongside your cell lysate samples; the antibody detects the active-form band at ~57–60 kDa (HEK293-glycosylated) and should produce a clean signal at standard WB dilutions. Because both reagents are from the same source lot validation, this pairing eliminates the ambiguity of cross-reactivity with other MMP family members that frequently complicates MMP-18 Western blot interpretation.

How much recombinant MMP-18 should I load as a positive control on a Western blot, and what band should I expect?

Load 20–50 ng of REC-MMP18 per lane for a strong, reproducible positive control band. On a 10% or 4–12% gradient SDS-PAGE gel under reducing conditions, expect the primary band at 57–60 kDa (glycosylated active form). A faint secondary band at ~47–50 kDa may appear if minor propeptide processing occurs during storage — this is not a contamination artifact. Use with RP-MMP18 at the manufacturer's recommended WB dilution. If signal is weak, increasing REC-MMP18 to 50 ng is more reliable than increasing antibody concentration, which raises background.

What are the storage conditions and shelf life for recombinant MMP-18, and how should I handle it after thawing?

Store REC-MMP18 at -20°C in single-use aliquots in its supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol). Shelf life is 12 months from receipt under these conditions. After thawing, keep on ice and use within 4–6 hours; repeated freeze-thaw cycles degrade collagenase activity measurably by the second cycle. Do not dilute into water alone — always maintain CaCl₂ and at least 0.1 mg/mL carrier protein (BSA) if working below 10 nM to prevent adsorptive loss to tube walls. Purity is >90–95% by SDS-PAGE; endotoxin is <0.1 EU/µg by LAL.

Validation imagery coming soon

Western blot validation figures for REC-MMP18 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →